...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >IDENTIFICATION OF INHIBITORS OF DENGUE VIRUS (DENV1, DENV2 AND DENV3) NS2B/ NS3 SERINE PROTEASE: A MOLICULAR DOCKING AND SIMULATION APPROACH
【24h】

IDENTIFICATION OF INHIBITORS OF DENGUE VIRUS (DENV1, DENV2 AND DENV3) NS2B/ NS3 SERINE PROTEASE: A MOLICULAR DOCKING AND SIMULATION APPROACH

机译:登革热病毒(DENV1,DENV2和DENV3)NS2B / NS3丝氨酸蛋白酶抑制剂的鉴定:分子对接和模拟方法

获取原文

摘要

Dengue is one of the fatal diseases, which are becoming a global health burden from few decades. Dengue fever, dengue hemorrhagic fever anddengue shock syndrome, caused by dengue virus (DENV), which completes its life cycle in mosquito i.e. Aedes aegyti, and human (DENV), and infectabout various individuals every year. The objective of this study is to find a potent inhibitor of DENV (DENV1, DENV2 and DENV3). In the presentstudy, NS2b/NS3 serine protease complex in targeted for the screening of the suitable inhibitors for DENV (DENV1, DENV2 and DENV 3). Therefore,the NS2b/NS3 serine protease complex structures were retrieved from the RCSB Protein Databank. The unliganded protein structures were docked,and best three selected and analyzed. A molecular dynamic simulation is also performed to investigate the conformational and positional changesof ligand that provide insights into the binding stability. It was observed that three of screened compounds have the maximum potential against theprotein. The analysis was performed on the basis of scoring and binding ability and one of them indicated minimum energy score with high numberof interactions with active site residues and the simulation study revealed that this selected ligand could efficiently bind to the NS2b/NS3 protease.These findings conclude that this selected ligand could be a promising inhibitor of all three serotypes of DENV as drug targets.
机译:登革热是致命疾病之一,几十年来正成为全球健康负担。由登革热病毒(DENV)引起的登革热,登革出血热和登革热休克综合症,其在蚊子(即伊蚊和人类)中的生命周期得以完成,并且每年感染各种个体。这项研究的目的是找到一种有效的DENV抑制剂(DENV1,DENV2和DENV3)。在本研究中,NS2b / NS3丝氨酸蛋白酶复合物的目标是筛选合适的DENV抑制剂(DENV1,DENV2和DENV 3)。因此,从RCSB蛋白质数据库检索了NS2b / NS3丝氨酸蛋白酶复合物结构。将未结合的蛋白质结构对接,并选择和分析最佳的三个。还进行了分子动力学模拟,以研究配体的构象和位置变化,从而了解结合稳定性。观察到筛选出的三种化合物对蛋白质具有最大的潜力。分析是在得分和结合能力的基础上进行的,其中之一表明最低能量得分,且与活性位点残基发生大量相互作用,模拟研究表明该选定的配体可以有效结合NS2b / NS3蛋白酶。这种选择的配体可能是所有三种DENV血清型作为药物靶标的有前途的抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号